The term Axial Spondyloarthritis covers both the early inflammatory phase of the disease in which there is no structural damage in the sacroiliac joints (non-radiographic disease) and the later stages in which structural damage is visible on X‑ray scans of the sacroiliac joints as erosions, sclerosis or bony bridges (radiographic disease; also known as ankylosing spondylitis). In addition, patients with radiographic axial spondyloarthritis might have abnormalities in X‑ray scans of the spine, the most important one being syndesmophytes (vertical bony growth between the corners of two vertebral bodies).
Axial spondyloarthritis is divided into non-radiographic and radiographic disease (also known as ankylosing spondylitis) according to the presence of radiographic changes of the sacroiliac joints. Changes in the spine evident on X-ray can occur in radiographic axial spondyloarthritis, but spinal radiographs can also be normal.
DelveInsight’s, “Axial Spondyloarthritis Pipeline Insight, 2021” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/axial-spondyloarthritis-pipeline-insight
Some of the Axial Spondyloarthritis Companies are:
- Pfizer
- Mycenax Biotech
- Clover Biopharmaceuticals
- Celltrion
- UCB
- Gilead Sciences
- Amgen
- Genrix (Shanghai) Biopharmaceuticals
- Sun Pharma Global
- Boehringer Ingelheim
- Jiangsu HengRui Medicine
- Izana Bioscience
- 3SBio
- Tasly Pharmaceuticals Inc.
- Suzhou Zelgen Biopharmaceuticals
- Affibody
- Kinevant Sciences
- Qyuns Therapeutics
- Akeso Biopharma
- Jiangsu HengRui Medicine Co., Ltd
- FunPep Co Ltd.
- Luye Pharma Group
- siRNAgen Therapeutics
- Aclaris Therapeutics
- Dice molecules
- And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/axial-spondyloarthritis-pipeline-insight
DelveInsight’s Axial Spondyloarthritis report covers around 200+ products under different phases of clinical development like:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Some of Axial Spondyloarthritis Therapies are:
- Tofacitinib
- ENIA11
- SCB-808
- CT-P17
- Bimekizumab
- Filgotinib
- Apremilast
- GR1501
- Tildrakizumab
- BI 730357
- SHR0302
- Namilumab
- SSS07
- Jitongning tablets
- Jaktinib
- ABY-035
- KIN-1901
- QX002N
- AK111
- SHR-1314
- FPP003
- TS8108
- Amphisiran
- And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/axial-spondyloarthritis-pipeline-insight
Current Axial Spondyloarthritis Treatment Scenario and Axial Spondyloarthritis Emerging Therapies:
- How many companies are developing Axial spondyloarthritis drugs?
- How many Axial spondyloarthritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Axial spondyloarthritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Axial spondyloarthritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Axial spondyloarthritis and their status?
- What are the key designations that have been granted to the emerging drugs?
Request for Free Sample Report: https://www.delveinsight.com/sample-request/axial-spondyloarthritis-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Axial Spondyloarthritis: Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Axial spondyloarthritis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Axial spondyloarthritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Axial spondyloarthritis Collaboration Deals
Late Stage Products (Phase III)
• Comparative Analysis
Bimekizumab: UCB Biopharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Namilumab: Izana Bioscience
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
KIN-1901: Kinevant Sciences
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Axial spondyloarthritis Key Companies
Axial spondyloarthritis Key Products
Axial spondyloarthritis- Unmet Needs
Axial spondyloarthritis- Market Drivers and Barriers
Axial spondyloarthritis- Future Perspectives and Conclusion
Axial spondyloarthritis Analyst Views
Axial spondyloarthritis Key Companies
Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/axial-spondyloarthritis-axspa-pipeline-insight